top of page

What We Do


Inflection’s pipeline programs were licensed from the Spanish National Cancer Research Centre (CNIO) following an extensive global in-licensing process. The CNIO has a global reputation for excellence in cancer research and has its own drug discovery program.

The pipeline comprises of IBL-101, an oral, pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease, IBL-202, selected from a series of unique dual mechanism kinase inhibitors and AUM302 (formerly IBL-302), partnered with AUM Biosciences.

Screenshot 2022-05-29 at 21.32.01.png
bottom of page